Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Legend Biotech (LEGN – Research Report), Altimmune (ALT – Research Report) and Apellis Pharmaceuticals (APLS – Research Report).
Legend Biotech (LEGN)
Jefferies analyst Kelly Shi maintained a Buy rating on Legend Biotech yesterday and set a price target of $93.00. The company’s shares closed last Thursday at $59.05.
According to TipRanks.com, Shi is a 1-star analyst with an average return of
Currently, the analyst consensus on Legend Biotech is a Strong Buy with an average price target of $88.10, which is a 50.8% upside from current levels. In a report issued on January 3, RBC Capital also maintained a Buy rating on the stock with a $85.00 price target.
See today’s best-performing stocks on TipRanks >>
Altimmune (ALT)
In a report released yesterday, Roger Song from Jefferies maintained a Buy rating on Altimmune, with a price target of $35.00. The company’s shares closed last Thursday at $11.49.
According to TipRanks.com, Song is ranked 0 out of 5 stars with an average return of
Altimmune has an analyst consensus of Strong Buy, with a price target consensus of $21.83, a 94.0% upside from current levels. In a report issued on January 8, JMP Securities also reiterated a Buy rating on the stock with a $25.00 price target.
Apellis Pharmaceuticals (APLS)
Wedbush analyst Laura Chico maintained a Hold rating on Apellis Pharmaceuticals today and set a price target of $60.00. The company’s shares closed last Thursday at $66.09.
According to TipRanks.com, Chico is a 2-star analyst with an average return of
Currently, the analyst consensus on Apellis Pharmaceuticals is a Moderate Buy with an average price target of $67.92, which is a -2.2% downside from current levels. In a report issued on January 8, Mizuho Securities also maintained a Hold rating on the stock with a $49.00 price target.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on LEGN:
- Legend Biotech initiated with a Sector Perform at Scotiabank
- Legend Biotech reports outcomes in CARTITUDE-4 study of CARVYKTI
- Citi opens ‘positive catalyst watch’ on Legend Biotech
- There’s an Opportunity Brewing in These 3 Stocks, Says Goldman Sachs
- Cabaletta Bio, Gracell slide as FDA probes risk of CAR T cell immunotherapies
